DPX-Survivac Responses Now Up to 16 Months in Advanced Ovarian Cancer Trial
News
IMV‘s immunotherapy DPX-Survivac plus low-dose chemotherapy continues to show sustained benefits in people with heavily treated advanced ovarian cancer, with some benefits lasting up to 16 months, updated findings from a ... Read more